Efficacy of Notal Vision Home OCT demonstrated by a series of scientific and clinical work
29 juin 2022 08h00 HE | Notal Vision
Manassas, VA, June 29, 2022 (GLOBE NEWSWIRE) -- Notal Vision, Inc. reported today that numerous scientific and clinical publications and presentations prove the feasibility and efficacy of their...
Retrospective study covering 2,000 patients over 10 years using ForeseeHome AMD remote monitoring shows substantially better outcomes for patients
26 avr. 2022 08h49 HE | Notal Vision
Manassas, VA, April 26, 2022 (GLOBE NEWSWIRE) -- Notal Vision, Inc. reported today the publication of the Analysis of Long-term visual Outcomes of ForeseeHome Remote Telemonitoring (ALOFT) study...
Notal Vision Reports Publication of First U.S. Home OCT Study Results
08 mars 2022 09h48 HE | Notal Vision
Manassas, VA, March 08, 2022 (GLOBE NEWSWIRE) -- Manassas, VA (March 8th, 2022) – Digital healthcare provider Notal Vision today announced that results of the first U.S.-based study with its...
Notal Vision Monitoring Center Reports AI Analysis of 10 Million ForeseeHome® AMD Home Monitoring Tests
30 nov. 2021 08h00 HE | Notal Vision
Manassas, VA, Nov. 30, 2021 (GLOBE NEWSWIRE) -- The Notal Vision Monitoring Center celebrates the artificial intelligence (AI) based analysis of the ten millionth test performed by over 20,000...
Notal Vision Reports Results from First U.S. Home OCT Feasibility Study
12 oct. 2021 08h00 HE | Notal Vision
Manassas, VA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc. reported today that results of the first U.S.-based feasibility study with its investigational home-based optical coherence...
Notal Vision announces publication of first prospective longitudinal pilot study of daily self-imaging with patient-operated Home OCT in wet AMD patients
13 juil. 2021 08h00 HE | Notal Vision
Manassas, VA, July 13, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc. announced today that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their...
Notal Vision raises up to $60 million to support development of its Home OCT technology and commercial growth of its ForeseeHome AMD Monitoring Program
01 juin 2021 08h00 HE | Notal Vision
Manassas, VA, June 01, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc., a privately held ophthalmic home monitoring services provider focused on early disease detection and treatment monitoring is...
ForeseeHome AMD home monitoring real-world data analysis demonstrates substantial benefit for patients’ vision
06 avr. 2021 08h00 HE | Notal Vision
Manassas, VA, April 06, 2021 (GLOBE NEWSWIRE) -- Real-world data on the performance of the ForeseeHome® AMD Monitoring Program, a home-based diagnostic that helps detect the conversion from...
AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials
23 févr. 2021 08h00 HE | Notal Vision
Manassas, VA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc. announced today that the company will provide AsclepiX Therapeutics with Home OCT monitoring services through its Notal Vision...
Notal Vision Launches First U.S. Home OCT Longitudinal Study with Patient Self-operated Device
12 janv. 2021 08h00 HE | Notal Vision
Manassas, VA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc. announced today that the company initiated the first US-based study using its investigational home-based optical coherence...